Literature DB >> 26811112

Predictors of vaginal mesh exposure after midurethral sling placement: a case-control study.

Brian J Linder1, Sherif A El-Nashar2, Daniel A Carranza Leon2, Emanuel C Trabuco2.   

Abstract

INTRODUCTION AND HYPOTHESIS: Female stress urinary incontinence is highly prevalent, and synthetic midurethral sling placement is the most common type of anti-incontinence surgery performed in the USA. We aimed to identify risk factors associated with surgery used to treated vaginal mesh exposure after midurethral sling placement for stress urinary incontinence.
METHODS: We identified women who underwent anti-incontinence procedures from January 2002 through December 2012. Patients with vaginal mesh exposure undergoing surgical repair after midurethral sling placement were compared with a control group without mesh exposure in a 1:3 ratio. Patients with ObTape sling placement (Mentor Corporation) were excluded. Logistic regression models were used to evaluate associations between clinical risk factors and vaginal mesh exposure.
RESULTS: Overall, 2,123 patients underwent primary sling placement, with 27 (1.3 %) having vaginal mesh exposure necessitating surgical repair. Patients with mesh exposure were more likely to have undergone previous bariatric surgery (P = 0.008), hemoglobin <13 g/dL (P = 0.006), premenopausal status (P = 0.008), age <50 years (P = 0.001), and the retropubic approach to sling placement (P = 0.03). Multivariate analysis identified these risk factors: previous bariatric surgery (odds ratio [OR], 7.0; 95 % CI, 1.1-61.4), retropubic approach (OR, 5.7; 95 % CI, 1.1-107.0), preoperative hemoglobin <13 g/dL (OR, 2.8; 95 % CI, 1.1-7.5), and premenopausal status (OR, 2.6; 95 % CI, 1.0-7.3). Among postmenopausal patients, those with mesh exposure were significantly more likely to receive preoperative estrogen therapy (OR, 12.4; 95 % CI, 2.7-57.8).
CONCLUSIONS: Previous bariatric surgery, retropubic approach, premenopausal status, and lower preoperative hemoglobin were associated with a significantly increased risk of surgery for vaginal mesh exposure after midurethral sling placement. Recognizing these factors can improve preoperative patient counseling.

Entities:  

Keywords:  Bariatric surgery; Complication; Midurethral sling; Vaginal exposure

Mesh:

Year:  2016        PMID: 26811112     DOI: 10.1007/s00192-016-2947-2

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  20 in total

1.  Tobacco use is a risk factor for mesh erosion after abdominal sacral colpoperineopexy.

Authors:  Joye K Lowman; Patrick J Woodman; Patrick A Nosti; Richard C Bump; Colin L Terry; Douglass S Hale
Journal:  Am J Obstet Gynecol       Date:  2008-04-02       Impact factor: 8.661

2.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

3.  Wound healing process in post-bariatric patients: an experimental evaluation.

Authors:  Marco D'Ettorre; Donatella Gniuli; Amerigo Iaconelli; Guido Massi; Geltrude Mingrone; Roberto Bracaglia
Journal:  Obes Surg       Date:  2010-11       Impact factor: 4.129

4.  Exploring predictors of mesh exposure after vaginal prolapse repair.

Authors:  Larry T Sirls; Gregory P McLennan; Kim A Killinger; Judith A Boura; Melissa Fischer; Pradeep Nagaraju; Kenneth Peters
Journal:  Female Pelvic Med Reconstr Surg       Date:  2013 Jul-Aug       Impact factor: 2.091

5.  Regression modelling strategies for improved prognostic prediction.

Authors:  F E Harrell; K L Lee; R M Califf; D B Pryor; R A Rosati
Journal:  Stat Med       Date:  1984 Apr-Jun       Impact factor: 2.373

6.  Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery.

Authors:  Jennifer M Wu; Catherine A Matthews; Mitchell M Conover; Virginia Pate; Michele Jonsson Funk
Journal:  Obstet Gynecol       Date:  2014-06       Impact factor: 7.661

7.  Prevalence and trends of symptomatic pelvic floor disorders in U.S. women.

Authors:  Jennifer M Wu; Camille P Vaughan; Patricia S Goode; David T Redden; Kathryn L Burgio; Holly E Richter; Alayne D Markland
Journal:  Obstet Gynecol       Date:  2014-01       Impact factor: 7.661

Review 8.  Potential impacts of nutritional deficiency of postbariatric patients on body contouring surgery.

Authors:  Siamak Agha-Mohammadi; Dennis J Hurwitz
Journal:  Plast Reconstr Surg       Date:  2008-12       Impact factor: 4.730

Review 9.  Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review.

Authors:  Lars Tue Sørensen
Journal:  Ann Surg       Date:  2012-06       Impact factor: 12.969

10.  Urethral erosion after synthetic and nonsynthetic pubovaginal slings: differences in management and continence outcome.

Authors:  Cindy L Amundsen; Brian J Flynn; George D Webster
Journal:  J Urol       Date:  2003-07       Impact factor: 7.450

View more
  4 in total

1.  Autologous transobturator midurethral sling.

Authors:  Alkan Çubuk; Akif Erbin; Metin Savun; Ali Ayrancı; Burak Üçpınar; Fatih Yanaral; Ömer Sarılar; Şeref Basal; Mehmet Fatih Akbulut
Journal:  Turk J Urol       Date:  2018-12-21

Review 2.  Comparison of synthetic mesh erosion and chronic pain rates after surgery for pelvic organ prolapse and stress urinary incontinence: a systematic review.

Authors:  Eoin MacCraith; Eoghan M Cunnane; Michael Joyce; James C Forde; Fergal J O'Brien; Niall F Davis
Journal:  Int Urogynecol J       Date:  2020-11-25       Impact factor: 2.894

3.  The Outcome of Repeated Mid Urethral Sling in SUI Treatment after Vaginal Excisions of Primary Failed Sling: Preliminary Study.

Authors:  Jacek Kociszewski; Wojciech Majkusiak; Andrzej Pomian; Paweł Tomasik; Edyta Horosz; Andrzej Kuszka; Ewa Barcz
Journal:  Biomed Res Int       Date:  2016-11-23       Impact factor: 3.411

4.  Second-Line Surgical Management After Midurethral Sling Failure.

Authors:  Joonbeom Kwon; Yeonjoo Kim; Duk Yoon Kim
Journal:  Int Neurourol J       Date:  2021-03-29       Impact factor: 2.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.